Advanced Kidney Cancer (RCC): Clinical Trial Results With LENVIMA® (lenvatinib) Plus EverolimusAdvanced Kidney Cancer (RCC): Clinical Trial Results With LENVIMA® (lenvatinib) Plus Everolimus

Advanced kidney cancer and LENVIMA

Even though your advanced kidney cancer (renal cell carcinoma, or RCC) returning is unexpected, you could still have options for treatment. If your first RCC treatment has stopped working, LENVIMA may be an option for you. FDA-approved LENVIMA + everolimus is an oral combination prescription for people with advanced RCC whose first treatment with an anti-cancer medicine is no longer helping.

The combination treatment LENVIMA + everolimus was studied in a clinical trial of 153 people with advanced or metastatic RCC who were already treated with 1 prior anti-cancer medicine compared to everolimus alone.

A clinical study of LENVIMA + everolimus showed:

49% (25 out of 51 people) of people taking LENVIMA + everolimus together did not have their cancer get worse compared to only 26% (13 out of 50 people) on everolimus alone at the time of follow-up

LENVIMA +

everolimus

25 of 51 people
being treated with LENVIMA + everolimus did not have their cancer get worse

everolimus
alone

13 of 50 people
being treated with everolimus alone did not have their cancer get worse

The Median Time People With Advanced Kidney Cancer (RCC) Treated With LENVIMA® (lenvatinib) Plus Everolimus Did Not Have Their Cancer Get Worse Was 14.6 Months Compared to 5.5 Months for Those Treated With Everolimus Alone
14.6 months

was the median* time people treated with LENVIMA + everolimus together did not have their cancer get worse compared to 5.5 months for those treated with everolimus alone

*Median: The middle number in a list of numbers arranged from lowest to highest.

37% (19 out of 51 people) of people treated with LENVIMA + everolimus had their tumors either partially shrink (partial response) or become undetectable (complete response) compared to 6% (3 out of 50 people) treated with everolimus alone

19 of 51 people
had their tumors
shrink

LENVIMA +

everolimus

Partial Response: 35%
(18 of 51 people)

Complete Response: 2%
(1 of 51 people)

3 of 50 people
had their tumors
shrink

everolimus
alone

Partial Response: 6%
(3 of 50 people)

Complete Response: 0%
(0 of 50 people)

Everolimus Prescribing Information
Please also see the everolimus Prescribing Information or talk to your health care team for more information about everolimus.

How does LENVIMA work?

Understanding what LENVIMA is and how it may work can help set expectations for your treatment journey.